See the DrugPatentWatch profile for Fetzima
Fetzima is not approved for use in Canada. The drug, also known by its generic name levomilnacipran, is a serotonin-norepinephrine reuptake inhibitor (SNRI) [1]. It is approved in the United States for the treatment of adults with major depressive disorder (MDD) [2].
What is Fetzima used for?
Fetzima is prescribed to treat major depressive disorder (MDD) in adults [2]. It works by increasing the levels of certain natural substances in the brain that help regulate mood [3].
Why is Fetzima not available in Canada?
The specific reasons for Fetzima's lack of approval in Canada are not publicly detailed. Regulatory bodies in different countries review drugs independently, considering various factors such as clinical trial data, manufacturing processes, and the specific needs of their populations [4].
How does Fetzima compare to other antidepressants?
Fetzima belongs to the SNRI class of antidepressants, which includes medications like venlafaxine (Effexor) and duloxetine (Cymbalta) [5]. SNRIs work by affecting the levels of serotonin and norepinephrine in the brain, both of which are neurotransmitters believed to play a role in mood regulation [6]. Other classes of antidepressants include selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs), each with different mechanisms of action and side effect profiles [7].
What are the potential side effects of Fetzima?
Common side effects associated with Fetzima in the U.S. include nausea, dry mouth, constipation, insomnia, increased sweating, and decreased appetite [2]. Serious side effects, though less common, can include increased blood pressure, potential for suicidal thoughts or behaviors, and serotonin syndrome [8].
When might Fetzima become available in Canada?
There is no publicly available information indicating if or when Fetzima might be submitted for review or approved in Canada. Pharmaceutical companies decide which markets to pursue based on various commercial and regulatory considerations [4].
Where can I find more information on Fetzima?
For information regarding Fetzima's availability and use in regions where it is approved, such as the United States, resources like the U.S. Food and Drug Administration (FDA) and the drug's prescribing information are available [2]. Information on drug patents and exclusivity can be found on DrugPatentWatch.com [9].
Sources:
1. DrugPatentWatch.com
2. FDA U.S. Food & Drug Administration
3. National Institute of Mental Health
4. Health Canada
5. Mayo Clinic
6. American Psychiatric Association
7. National Alliance on Mental Illness
8. WebMD
9. DrugPatentWatch.com